ArticleNeuropathology and applied neurobiology2009
Expression of reticulon 3 in Alzheimer's disease brain.
Article in Neuropathology and applied neurobiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Circ_0043947 contributes to interleukin 1β-induced injury in chondrocytes by sponging miR-671-5p to up-regulate RTN3 expression in osteoarthritis pathology.Journal of orthopaedic surgery and research · 2022Article
- Revelation of Pivotal Genes Pertinent to Alzheimer's Pathogenesis: A Methodical Evaluation of 32 GEO Datasets.Journal of molecular neuroscience : MN · 2022Article
- Biological roles of the B cell receptor-associated protein 31: Functional Implication in Cancer.Molecular biology reports · 2021Review
- Role of Endoplasmic Reticulum-Associated Proteins in Flavivirus Replication and Assembly Complexes.Pathogens (Basel, Switzerland) · 2019Review
- RTN3 Regulates the Expression Level of Chemokine Receptor CXCR4 and is Required for Migration of Primordial Germ Cells.International journal of molecular sciences · 2016Article
- Proteolytic control of neurite outgrowth inhibitor NOGO-A by the cAMP/PKA pathway.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Impact of RTN3 deficiency on expression of BACE1 and amyloid deposition.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- The role of reticulons in neurodegenerative diseases.Neuromolecular medicine · 2014Review
- Exploring the contribution of estrogen to amyloid-Beta regulation: a novel multifactorial computational modeling approach.Frontiers in pharmacology · 2013Article
- Development of a specific ELISA to measure BACE1 levels in human tissues.Journal of neuroscience methods · 2011Article
- Widespread distribution of reticulon-3 in various neurodegenerative diseases.Neuropathology : official journal of the Japanese Society of Neuropathology · 2010Article
- RTN/Nogo in forming Alzheimer's neuritic plaques.Neuroscience and biobehavioral reviews · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
aimsReticulon 3 (RTN3), a member of the reticulon family of proteins, interacts with the beta-secretase, beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1), and inhibits its activity to produce beta-amyloid protein. The aim of the present study was to clarify the biological role of RTN3 in the brain and its potential involvement in the neuropathology of Alzheimer's disease (AD).
methodsWe performed immunohistochemical and biochemical analyses using a specific antibody against RTN3 to investigate the expression and subcellular localization of RTN3 in control and AD brain tissue samples.
resultsWestern blot analysis revealed no significant differences in the RTN3 levels between control and AD brains. Immunohistochemical staining showed that RTN3 immunoreactivity was predominantly localized in pyramidal neurones of the cerebral cortex. The patterns of RTN3 immunostaining were similar in control and AD cerebral cortices, and senile plaques were generally negative for RTN3. Biochemical subcellular fractionation disclosed that RTN3 colocalized with BACE1 in various fractions, including the endoplasmic reticulum and the Golgi apparatus. Double-immunofluorescence staining additionally indicated that RTN3 was localized in both endoplasmic reticulum and Golgi compartments in neurones.
conclusionsThese results show that RTN3 is primarily expressed in pyramidal neurones of the human cerebral cortex and that no clear difference of RTN3 immunoreactivity is observable between control and AD brains. Our data also suggest that there is considerable colocalization of RTN3 with BACE1 at a subcellular level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.